At a Glance : Discover the transformative potential of Spravato (esketamine) therapy at Seaside Ketamine in Newport Beach! If you’re dealing with treatment-resistant depression, anxiety, or PTSD, our solutions provide rapid relief when standard treatments fail. Spravato, an FDA-approved nasal spray, is a valuable alternative with established insurance pathways for qualifying patients. Experience Ketamine-Assisted Psychotherapy and confront trauma with less fear. Don’t let anxiety or depression hold you back—schedule your free consultation today and take the first step towards a brighter future! Your journey to renewed hope starts here.
For Newport Beach patients with treatment-resistant depression who have been deterred by the cost of IV ketamine therapy, Spravato (esketamine) represents a critically important alternative. It is FDA-approved, it has established insurance coverage pathways for qualifying patients, and it is available at Seaside Ketamine’s Newport Beach location.
Spravato is the brand name for esketamine — a nasal spray formulation of a ketamine derivative developed and approved by Johnson & Johnson’s Janssen Pharmaceuticals. It received FDA approval in 2019 for treatment-resistant depression (TRD) and subsequently received additional approval for major depressive disorder with acute suicidal ideation or behavior (MDD-SI).
Esketamine is the S-enantiomer of ketamine — a specific molecular form rather than the racemic mixture used in IV ketamine infusions. It is administered as a nasal spray under clinical supervision at a certified treatment site.
Treatment-Resistant Depression (TRD): Major depressive disorder in adults who have not responded adequately to at least two different antidepressant treatments. This is the most common qualifying pathway.
MDD with Acute Suicidal Ideation or Behavior (MDD-SI): Major depressive disorder in adults currently experiencing active suicidal ideation with intent or behavior, used alongside standard-of-care treatment.
If you’ve tried two or more antidepressants at adequate doses for adequate duration without achieving remission, you are likely clinically eligible under the TRD indication.
Because Spravato has FDA approval, it has established pathways for coverage through most major commercial insurance plans, Medicare, and Medi-Cal for qualifying patients. Coverage requires prior authorization and documentation of TRD diagnosis and prior antidepressant failure — but for eligible patients, insurance can cover the substantial majority of treatment cost.
Seaside Ketamine Newport Beach assists patients with insurance verification and prior authorization before beginning treatment.
Spravato is administered at our Newport Beach clinic under clinical supervision, with a mandatory 2-hour monitoring period following each session. The treatment schedule follows a structured protocol: twice weekly for four weeks, once weekly for four weeks, then once weekly or biweekly as maintenance. The nasal spray is self-administered by the patient under physician supervision.
Cost and insurance access favor Spravato for eligible patients. Experience and dose precision favor IV ketamine. Protocol fit varies by patient — IV’s compressed series suits those wanting rapid results in a shorter window; Spravato’s longer ongoing schedule suits patients preferring a gradual, maintained cadence. For certain presentations — particularly MDD with acute suicidal ideation — Spravato’s FDA indication makes it the clinically appropriate starting point. Dr. Gillin will advise on the right option for your specific situation.
Contact your insurance provider directly and ask about Spravato (esketamine) coverage under your plan for treatment-resistant depression. Ask specifically whether prior authorization is required, what clinical documentation is needed, and what your in-network coverage looks like for a certified Spravato treatment site. Seaside Ketamine Newport Beach can also assist with the verification process during your intake consultation — we have experience navigating prior authorization requirements across the major commercial insurers in Orange County.
Yes — this is an FDA requirement, not a clinic preference. Because Spravato can cause dissociation and sedation following administration, all patients must be monitored at the certified treatment site for a minimum of two hours after each dose. You will not be able to drive yourself home after any Spravato session and will need a driver or rideshare. We recommend treating Spravato session days as rest days with no significant obligations scheduled immediately afterward.
Direct head-to-head comparison trials are limited, making a definitive efficacy comparison difficult. Both have demonstrated meaningful antidepressant effects in TRD. IV ketamine has a larger overall research base; Spravato has FDA approval and more rigorous Phase III trial data supporting its specific indications. In practice, both are effective for appropriate candidates. The choice is guided less by a clear efficacy winner and more by clinical picture, insurance coverage, cost, and patient preference — all of which Dr. Gillin discusses directly with you during your consultation.
